Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants. [PDF]
Fullarton J +5 more
europepmc +1 more source
Detection of nirsevimab-resistant RSV-B variants in children carrying the F:N201T substitution through genomic surveillance, Spain, 2025/26 season. [PDF]
Iglesias-Caballero M +15 more
europepmc +1 more source
Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab: A FAERS Observational Study. [PDF]
Touffaha I, Ablah E, Okut H, Homan G.
europepmc +1 more source
RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness. [PDF]
Oliva IO, Oliveira CR.
europepmc +1 more source
Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants. [PDF]
Rodriguez-Martinez CE +12 more
europepmc +1 more source
Insights Into monoclonal antibodies and vaccines targeting respiratory viruses. [PDF]
Gambadauro A +3 more
europepmc +1 more source
Pediatricians' attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey. [PDF]
Di Chiara C +16 more
europepmc +1 more source
Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab. [PDF]
Sincero SR +7 more
europepmc +1 more source
A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention. [PDF]
Salahi Ardekani O +8 more
europepmc +1 more source
CXCL13 and IL-33 as Immunomodulatory Adjuvants Combined with Respiratory Syncytial Virus Fusion (RSV F) Protein to Enhance Mucosal RSV Vaccination. [PDF]
Alnajran H +12 more
europepmc +1 more source

